All In Biotech

Drug Trial Radar · NCT01931670

A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

Last checked: Nov 19, 2026Latest source record: Sep 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 815 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

815

Actual

Start

Sep 9, 2013

Primary completion

Jan 6, 2016

Study completion Dec 19, 2016

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Aug 29, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 49 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized study evaluating the safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in adult premenopausal female subjects.

Conditions

  • Endometriosis

Interventions

  • placeboOther

  • ElagolixDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Responders at Month 3 Based on Daily Assessment of Dysmenorrhea (DYS)Time frame: At Month 3 of the Treatment Period
  2. Percentage of Responders at Month 3 Based on Daily Assessment of Non-Menstrual Pelvic Pain (NMPP)Time frame: At Month 3 of Treatment Period

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.